Study of PF-07248144 in Advanced or Metastatic Solid Tumors
← catalyst calendarNCT04606446 · readout in 1,059 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
320estimated
Sites
44
Countries
Australia, China, Japan +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-16 | actual | When the study began enrolling |
| Primary completion | 2029-07-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-10 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
- Drug: PF-07248144
- Drug: Fulvestrant — also filed as Faslodex
- Drug: Letrozole — also filed as Femara
- Drug: Palbociclib — also filed as Ibrance
- Drug: PF-07220060
- Drug: PF-07850327, ARV-471, vepdegestrant
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose-limiting toxicities in the Dose Escalation Arms.
measured Up to 29 days
Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.
measured Up to 24 months
Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.
measured Up to 24 months
Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms
measured Up to 24 months
Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms
measured Up to 24 months
Publications
- PMID 38824244 — linked by the registry
- PMID 37127754 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed